Dianthus Therapeutics, Inc. (DNTH) Dividend History

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for rare and life-threatening diseases. The company utilizes innovative approaches in protein engineering and drug discovery to create treatments that address unmet medical needs, particularly in the fields of hematology and immunology. Founded with the goal of advancing precision medicine, Dianthus aims to improve patient outcomes through its specialized therapeutics.

300 Technology Square, Cambridge, MA, 02139
Phone: 857-201-2700
Website: https://www.dianthustx.com

Dividend History

Dianthus Therapeutics, Inc. currently does not pay dividends

Company News

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

Dianthus Therapeutics has completed enrollment in the Phase 2 MaGic trial of its investigational drug DNTH103 for generalized Myasthenia Gravis. Top-line results are expected in September 2025. DNTH103 is also being evaluated in trials for Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy.

GlobeNewswire Inc.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Dianthus Therapeutics reported positive progress in its clinical trials for DNTH103, a potential best-in-class treatment for autoimmune diseases. The company has a strong cash position and is on track to report key data readouts in the coming years.

GlobeNewswire Inc.
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

Dianthus Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming healthcare investor conferences, where its CEO will present the company's progress in developing next-generation antibody complement therapeutics for severe autoimmune and inflammatory diseases.

GlobeNewswire Inc.
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Dianthus Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming healthcare investor conferences in November and December 2024. The company is dedicated to developing novel antibody complement therapeutics for severe autoimmune and inflammatory diseases.

GlobeNewswire Inc.
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 05:32:34 UTC